[go: up one dir, main page]

NO20024386L - Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer - Google Patents

Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer

Info

Publication number
NO20024386L
NO20024386L NO20024386A NO20024386A NO20024386L NO 20024386 L NO20024386 L NO 20024386L NO 20024386 A NO20024386 A NO 20024386A NO 20024386 A NO20024386 A NO 20024386A NO 20024386 L NO20024386 L NO 20024386L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
glycogen phosphorylase
phosphorylase inhibitors
inhibitors
glycogen
Prior art date
Application number
NO20024386A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024386D0 (no
Inventor
Dennis Jay Hoover
Ravi Mysore Shanker
Dwayne Thomas Friesen
Douglas Alan Lorenz
James Alan Schrive Nightingale
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20024386D0 publication Critical patent/NO20024386D0/no
Publication of NO20024386L publication Critical patent/NO20024386L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20024386A 2000-03-16 2002-09-13 Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer NO20024386L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (fr) 2000-03-16 2001-03-16 Compositions pharmaceutiques d'inhibiteurs du glycogene phosphorylase

Publications (2)

Publication Number Publication Date
NO20024386D0 NO20024386D0 (no) 2002-09-13
NO20024386L true NO20024386L (no) 2002-11-13

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024386A NO20024386L (no) 2000-03-16 2002-09-13 Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer

Country Status (32)

Country Link
US (1) US20010053778A1 (fr)
EP (1) EP1263414A1 (fr)
JP (1) JP2003526654A (fr)
KR (1) KR20020081445A (fr)
CN (1) CN1418089A (fr)
AP (1) AP2002002621A0 (fr)
AR (1) AR027656A1 (fr)
AU (1) AU2001242669A1 (fr)
BG (1) BG107037A (fr)
BR (1) BR0109189A (fr)
CA (1) CA2403241A1 (fr)
CO (1) CO5280087A1 (fr)
CZ (1) CZ20022955A3 (fr)
EA (1) EA200200858A1 (fr)
EE (1) EE200200530A (fr)
HU (1) HUP0204583A2 (fr)
IL (1) IL151320A0 (fr)
IS (1) IS6508A (fr)
MA (1) MA26882A1 (fr)
MX (1) MXPA02009097A (fr)
NO (1) NO20024386L (fr)
OA (1) OA12232A (fr)
PA (1) PA8513601A1 (fr)
PE (1) PE20011184A1 (fr)
PL (1) PL360780A1 (fr)
SK (1) SK12622002A3 (fr)
SV (1) SV2002000343A (fr)
TN (1) TNSN01040A1 (fr)
TR (1) TR200202184T2 (fr)
WO (1) WO2001068055A1 (fr)
YU (1) YU67202A (fr)
ZA (1) ZA200207290B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2002070478A1 (fr) 2001-03-06 2002-09-12 Astrazeneca Ab Dérivés indolone capable de dégrader des vaisseaux
ATE486586T1 (de) * 2001-06-22 2010-11-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
ES2878403T3 (es) 2002-02-01 2021-11-18 Bend Res Inc Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
RU2288703C2 (ru) 2002-02-01 2006-12-10 Пфайзер Продактс Инк. Способ создания однородных высушенных распылением твердых аморфных лекарственных дисперсных систем с использованием распыляющих напорных форсунок (варианты) и продукт
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005011635A2 (fr) * 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2548376A1 (fr) * 2003-12-31 2005-07-21 Pfizer Products Inc. Compositions solides a base de medicaments peu solubles et de poloxameres
WO2005085245A1 (fr) 2004-03-08 2005-09-15 Prosidion Limited Hydrazides d'acide pyrrolopyridine-2-carboxylique utilises comme inhibiteurs de la glycogene phosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
US20140179749A1 (en) 2012-09-11 2014-06-26 Bend Research Formulations of enzalutamide
CA3128535C (fr) 2013-07-19 2024-10-15 Siga Technologies, Inc. Preparation de tecovirimat amorphe
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP624A (en) * 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
CA2342471C (fr) * 1995-06-06 2002-10-29 Judith L. Treadway Intermediaires amines de carbonyle-methyle heterocycliques
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
PL360780A1 (en) 2004-09-20
HUP0204583A2 (hu) 2003-04-28
TNSN01040A1 (fr) 2005-11-10
IL151320A0 (en) 2003-04-10
CN1418089A (zh) 2003-05-14
BG107037A (bg) 2003-04-30
AP2002002621A0 (en) 2002-09-30
AU2001242669A1 (en) 2001-09-24
MXPA02009097A (es) 2003-03-12
ZA200207290B (en) 2003-09-11
CA2403241A1 (fr) 2001-09-20
NO20024386D0 (no) 2002-09-13
TR200202184T2 (tr) 2003-01-21
SV2002000343A (es) 2002-07-03
MA26882A1 (fr) 2004-12-20
US20010053778A1 (en) 2001-12-20
PE20011184A1 (es) 2001-11-15
EA200200858A1 (ru) 2003-02-27
CZ20022955A3 (cs) 2003-09-17
EE200200530A (et) 2004-04-15
IS6508A (is) 2002-08-16
SK12622002A3 (sk) 2004-02-03
AR027656A1 (es) 2003-04-09
OA12232A (en) 2006-05-10
PA8513601A1 (es) 2004-08-31
WO2001068055A1 (fr) 2001-09-20
YU67202A (sh) 2006-01-16
BR0109189A (pt) 2003-05-27
EP1263414A1 (fr) 2002-12-11
KR20020081445A (ko) 2002-10-26
JP2003526654A (ja) 2003-09-09
CO5280087A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
NO20024386D0 (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
NO20030506D0 (no) Farmasöytiske sammensetninger av kolesterylesteroverföringsproteininhibitorer
HU0101158D0 (en) Use of glycogen phosphorylase inhibitors
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
PT1250343E (pt) Composicoes de antibioticos de azalida
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20001749L (fi) Farmaseuttisia koostumuksia
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
EE05020B1 (et) Glburiidi ravimkoostis
HUP0400327A3 (en) Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use
ZA200703713B (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20043902L (no) Kontrollert syntese av ziprasidon og sammensetninger derav
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
NO20014893D0 (no) Farmasöytiske sammensetninger av erythropoietin
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
IS7051A (is) Lyfjasamsetningar
IS7435A (is) Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasa
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
IL159085A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
NO20023785L (no) Vanndispergerbar formulering av paroxetin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application